An effective AstraZeneca vaccine booster shot against Omicron
(Reuters) – AstraZeneca (NASDAQ:) COVID-19 vaccine’s three-dose course is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from a study at an Oxford University lab.
The study, unpublished in a peer-reviewed medical journal, showed that antibody levels against Omicron were higher than antibodies in people infected with COVID-19 and naturally recovered.
After three doses of the vaccine, the levels of neutralization against Omicron were similar to those of the Delta variant of the virus after two doses, the company added.
The Anglo-Swedish pharmacist said the researchers at Oxford University were independent of those who had worked on the Vaxzevria vaccine with AstraZeneca.
Fusion Media or anyone involved with Fusion Media will not be held liable for any loss or damage as a result of relying on the information contained in the data, estimates, charts and buy / sell signals contained in this website. Please be informed that one of the most risky forms of investment possible is the full information on the risks and costs associated with trading in the financial markets.
Source link